Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
Fiche publication
Date publication
mars 2018
Journal
Heart (British Cardiac Society)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COTTIN Yves
Tous les auteurs :
Grimaldi-Bensouda L, Danchin N, Dallongeville J, Falissard B, Furber A, Cottin Y, Bonello L, Morel O, Leclercq F, Puymirat E, Ghanem F, Delarche N, Benichou J, Abenhaim L,
Lien Pubmed
Résumé
To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions.
Mots clés
Age Factors, Aged, Aspirin, therapeutic use, Case-Control Studies, Clopidogrel, therapeutic use, Drug Therapy, Combination, methods, Female, France, epidemiology, Humans, Male, Middle Aged, Myocardial Infarction, diagnosis, Platelet Aggregation Inhibitors, therapeutic use, Prasugrel Hydrochloride, therapeutic use, Recurrence, Registries, statistics & numerical data, Risk Factors, Secondary Prevention, methods, Sex Factors, Ticagrelor, therapeutic use
Référence
Heart. 2018 Mar 13;: